In the question period they emphasized that the change in the anticipated filing time did not stem from any negative event, just from a reassessment of the likely time frame. "Ongoing CNC studies, ongoing pilot PK." Targeting pivotal PK study as soon as possible.
The anticipated filing date for the Makena 3.0 sNDA has been pushed forward to Q2 2017, but on the positive side the FDA has confirmed that the review time will be only six months.
A lot of shorts want to cover, so perhaps big gyrations coming before liftoff in June. I see .85-.90 intraday coming this month. Hopefully we hold the line (s) to negate the Nas/Russell concerns.
Staying above 1 and remove Nasdaq warning is the first step.
We also need to stay around this price or higher (above $180MM market cap) by May 27, to also stay in the Russell.
I think May might be very interesting month......
Thanks for the heads up Loko on "Armistice Capital LLC boosted its stake in Antares Pharma by 59.5% in the fourth quarter. Armistice Capital LLC now owns 13,240,000 shares of the specialty pharmaceutical company’s stock." So now they own about 10% right?
Evidently you are not proficient in reading. I did not say that Zacks is a reliable source, but rather no news coming with an overbought condition means we drop and that would 'coincidentally' align with Zacks having a strong sell rating on ATRS right now. The twilight zone, that's where America is right now!!! The evidence, Trump winning!
Zacks? You must think we believe in the tooth fairy quoting Zacks. They are totally worthless and YOU know it. Anyone trades on the basis of a Zacks Buy or Sell rating must be truly #$%$. Nuff said.
I just hope we stay above $1 for the next 3 days-- Thursday a close above $1 and the Nasdaq delisting notice issued is invalidated.
Predicting EPI (BX) news coming 'AFTER' TEVA/ACTIVIS deal closes later in June along with SUMA launch. I anticipate nothing for this month, so Zacks sell rating on overbought condition is likely to validate in the short term.
Did I miss a prediction from ryman? I don't think so. btw, after the guys who care about the Russel get the desired 10 days above $1, all bets are off on further heavy interest on the Buy side. Unless there's a miracle and we get good news about Otrexup sales or some other big deal. Makena2 would be nice but with Antares it is better to have little to no hope and low expectations as these guys could ruin a wet dream-- always managing to disappoint. HOPING I'm wrong.
"So the timing's kinda' strange here. " The DBS conference has been in the books since when. Are you suggesting there is something strange that companies go there and present just because their earnings calls are coming up. Or do you suggest they should cancel an opportunity to promote the company?
There is no strange timing here unless of course DBS knew around six months abut.....what?
I think we are still a month and a half away from the break-out news... TA, double bottom, higher low time.
stockvadar, the suspicion is in the pudding. As long as price remains above $1, on a closing basis by and on Thursday, then the Nasdaq delisting notice goes by, by. I believe that is the reason why we are above $1. If we get no news, I see .85-.90 intra day after May 9th conference call. Again, assuming, which is a good assumption, we get no news from anywhere other then what we already know for sure.
Well den' da only tings to discuss in particular to da delima, is da ROW marketing of Otrexup, a certain kit with injectors of various volumes and 25 mg, and the partner with Endo on QST, and NF-QST.....
Just trying to unravel the dilemma.
Gooooo ATRS......Rock da world......